50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

NMC founder sues EY, banks and execs for $8 billion over alleged fraud

Published 07/22/2021, 02:06 PM
Updated 07/22/2021, 02:10 PM
© Reuters. The logo of Ernst & Young is seen in Zurich, Switzerland November 13, 2020. REUTERS/Arnd Wiegmann
WAT
-

By Abhirup Roy

MUMBAI (Reuters) - B.R. Shetty, the founder of stricken UAE hospital operator NMC Health, has sued auditor EY, two former top executives of his companies and two banks in a U.S. court, seeking $8 billion in damages for an alleged multibillion-dollar fraud at his group.

EY said in a statement: "We believe this case is without merit and we intend to defend it vigorously."

Several companies linked to the Indian entrepreneur ran into trouble last year after short-seller Muddy Waters (NYSE:WAT) questioned NMC's financial statements.

NMC subsequently announced far higher debts than it had previously reported and was later put into administration.

Shetty, now in India, is himself facing a criminal complaint in Abu Dhabi from one of NMC's lenders, Abu Dhabi Commercial Bank, and fighting court cases in India and Dubai as banks seek to recover loans from his companies. Last year, the UAE central bank ordered banks to freeze accounts of Shetty and members of his family, sources told Reuters.

Shetty has denied wrongdoing and says that he has been the victim of fraud.

In October, Shetty filed a complaint with Indian federal investigators, accusing brothers Prasanth and Promoth Manghat - respectively the former CEOs of NMC and Finablr, another Shetty group company -, along with their associates and bankers, of inflating the companies' balance sheets, arranging "illegal" credit facilities and misappropriating funds since 2012.

In the case filed last week at a U.S. Supreme Court in New York, Shetty repeated his allegations against the Manghat brothers and also said EY had issued fraudulent audits and financial reports while being aware of the laundering of illegally obtained loan proceeds.

"EY actively and intentionally conspired with the defendants to conceal their fraudulent conduct," Shetty said, according to a copy of the 105-page filing seen by Reuters.

He also alleged India's Bank of Baroda, through its New York and UAE branches, was a "principal conduit" for the fraudulent transactions, and Credit Europe Bank (CEB) in the Netherlands continued lending and earning fees despite being aware of the fraud.

A spokesperson for the Manghat brothers, who have denied Shetty's allegations, did not immediately respond to emails and phone calls seeking comment.

Bank of Baroda did not immediately respond to an email seeking comment outside of regular business hours.

© Reuters. The logo of Ernst & Young is seen in Zurich, Switzerland November 13, 2020. REUTERS/Arnd Wiegmann

CEB said in a statement that Shetty's allegations had "no legal or factual merit."

Shetty said in the court filing he had been "financially devastated" by the alleged fraud and that it had cost him more than $7 billion, while drugmaker Neopharma, in which he owns a 49% stake, had suffered more than $1 billion in damages.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.